Evotec AG has reached a milestone in its research alliance with Boehringer Ingelheim triggering a €2.0 million payment to Evotec. The milestone was for the transition of an oncology molecule into Phase I clinical trials.   Dr. Mario Polywka, chief operating officer of Evotec, said, “This is a very important 19th milestone for Evotec in our collaboration with Boehringer Ingelheim, as it represents the first oncology compound to progress into Phase I studies. The collaboration continues to d...